Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/64—Cyclic peptides containing only normal peptide links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/64—Cyclic peptides containing only normal peptide links
  • C07K7/645—Cyclosporins; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to a new cyclic peptide compound or a salt thereof having inhibitory activity against the RNA replication of hepatitis C virus (hereafter referred to as HCV) replicon.
• HCV hepatitis C virus
• the present invention relates to a new cyclic peptide compound or a salt thereof, to a process for preparation thereof, to a pharmaceutical composition comprising the new cyclic peptide compound or a salt thereof, and to a method for the prophylactic and/or therapeutic treatment of hepatitis C in a human being or animal.
• the estimated number of HCV carriers is about 170 million worldwide (about 3%) and about 1.5 million in Japan. Even in the combination therapy of using interferon
• IFN IFN-resistant virus
• ribavirin ribavirin
• HCV is a virus having plus-strand RNA as a gene and is classified into Flaviviridae in accordance with the analysis of the base sequence of the gene. According to Fields Virology fourth edition, D. Knipe et al ed., Philadelphia, Lippincott Williams & Wilkins 2001/ 1127-1161, although the existence of HCV was anticipated in 1970s, the discovery of HCV was very difficult. HCV was called non-A non-B hepatitis virus for many years.
• Cyclosporin A is used as an immunosuppressant for organ transplant.
• M. Thali et al., Nature 372, 363-365 (1994) . reported that Cyclosporin A had anti-HIV activity by inhibiting the interaction between Cyclosporin A and the virus particle forming protein of Human Immunodeficiency Virus Type 1 (HIV-I).
• R. M. Wenger et al. reported in WO00/01715 that their novel cyclosporins has the anti-HIV activity.
• Cyclosporine compounds it needs some severe conditions such as high temperature or high pressure.
• the conversion of the starting compound (FR901459 compound) to our compounds by a rearrangement reaction in the present invention needs the mild acidic condition because of the hydroxyl group on the 2-position of the starting compound.
• the object cyclic peptide compound in the present invention is a new compound, and can be represented by the following general formula (I):
• R 1 is hydrogen or lower alkyl
• R 2 is hydrogen, aryl or lower alkyl which is optionally substituted by a suitable substituent selected from the group consisting of: hydroxy, cyclo (lower) alkyl, lower alkoxy, aryl, aryl (lower) alkoxy, optionally substituted carbamoyloxy, and optionally substituted amino; and
• R 3 is cyclo (lower) alkyl, aryl, optionally substituted heterocyclic group or lower alkyl which is optionally substituted by a suitable substituent selected from the group consisting of: hydroxy, cyclo (lower) alkyl, lower alkoxy, aryl, aryl (lower ) alkoxy, lower alkoxy (lower) alkoxy, optionally substituted amino and -OC(O)NR 6 R 7 (wherein R 6 and R 7 are each independently hydrogen or lower alkyl, or alternatively R 6 and R 7 , together with the nitrogen atom to which they attached, represent N-containing heterocyclic group which is optionally substituted by a lower alkyl) ; and
• R 4 and R 5 are each independently hydrogen or lower alkyl; and represents single bond or double bond; alt thereof, with proviso, when R 2 is hydrogen, 'R 3 is cyclo (lower) alkyl, aryl, ' , optionally substituted heterocyclic group, lower alkoxymethyl, aryl (lower) alkyl, t-butyl, sec-butyl, cyclo (lower) alkyl (lower) alkyl, or ethyl substituted by a suitable substituent selected from the group consisting of hydroxy, lower alkoxy, aryl (lower) alkoxy, lower alkoxy (lower) alkoxy, optionally substituted amino and -OC(O)NR 6 R 7 (wherein R 6 and R 7 are each as defined above).
• Preferred embodiments of the object compound (I) are as follows.
• R 1 is hydrogen or lower alkyl
• R 2 is aryl or lower alkyl which is optionally substituted by a suitable substituent selected from the group consisting of: hydroxy, cyclo (lower ) alkyl, lower alkoxy, aryl, aryl (lower) alkoxy, di (lower) alkylcarbamoyloxy, and amino which is optionally substituted by one or two suitable substituent (s) selected from the group consisting of: lower alkyl, benzyloxycarbonyl and t- butoxycarbonyl ; and
• R 3 is cyclo (lower) alkyl, aryl, or lower alkyl which is optionally substituted by a suitable substituent selected from the group consisting of hydroxy, lower alkoxy, and aryl (lower) alkoxy;
• R 4 is hydrogen; and
• R 5 is lower alkyl; or a salt thereof.
• R 3 is aryl or lower alkyl which is optionally substituted by hydroxy or lower alkoxy;
• R 4 is hydrogen; and
• R 5 is lower alkyl;
• R 1 is lower alkyl
• R 2 is hydrogen
• R 3 is cyclo (lower) alkyl, aryl, heterocyclic group which is optionally substituted by lower alkoxy carbonyl, (lower) alkoxy (lower) alkyl, aryl (lower ) alkyl, t-butyl, sec-butyl, 1 ⁇ cyclo ( lower) alkyl (lower ) alkyl, or ethyl substituted by a suitable substituent selected from the group consisting of: hydroxy, lower alkoxy, aryl (lower ) alkoxy, lower alkoxy (lower) alkoxy, -OC(O)NR 6 R 7 (wherein R 6 and R 7 are each independently hydrogen or lower alkyl, or.
• R 6 and R 7 together with the nitrogen atom to which they attached, represent N- containing heterocyclic group which is optionally substituted by a lower alkyl), and amino which is optionally substituted by one or two suitable substituent (s) selected from the group consisting of: lower alkyl and benzyloxycarbonyl ; and
• R 4 and R 5 are each independently hydrogen or lower alkyl; or a salt thereof. 5) The compound of 4), wherein
• R 3 is cyclo ( lower) alkyl, aryl, heterocyclic group which is optionally substituted by lower alkoxy carbonyl, t-butyl, sec-butyl, or ethyl substituted by a suitable substituent selected from the group consisting of: hydroxy, lower alkoxy, aryl (lower ) alkoxy, lower alkoxy (lower) alkoxy, and -OC(O)NR 6 R 7 (wherein R 6 and R 7 are each independently hydrogen or lower alkyl, or alternatively R 6 and R 7 , together with the nitrogen atom to which they attached, represent N-, containing heterocyclic group which is optionally substituted by a lower alkyl) ;
• R 4 is hydrogen
• R 5 is lower alkyl; and moiety is double bond; or a salt thereof.
• X is ⁇ J ;
• R 3 is lower alkyl; and R 4 and R 5 are each independently hydrogen or lower alkyl; or a salt thereof.
• R is hydrogen; R 5 is lower alkyl; and moiety is double bond; or a salt thereof.
• the compound (I) or a salt thereof in the present invention can be prepared by the processes as illustrated in the following reaction schemes.
• X and Y are as defined above,
• L is a leaving group
• P is amino protective group
• n in the "n times" is 2 or 3.
• the object compound (Ia) or a salt thereof can be prepared from the compound (Ha) or a salt thereof by the following processes, a) introduction of protected amino acid
• This reaction is the amidation of the compound (Ha; with the compound (V) .
• the compound (V) is carboxylic acid (L is OH) or the reactive derivative thereof (including an acyl halide (e.g., carbonyl chloride, carbonyl bromide, and the like) , an acid anhydride, an activated ester (e.g., vinyl ester, propargyl ester, 2, 4-dinitrophenyl ester, pentafluorophenyl ester, methanesulfonylphenyl ester, dimethyliminomethyl ester, p-nitrophenyl thioester, an activated ester with a N-hydroxy compound (such as N-hydroxysuccinimide, N-hydroxybenzotriazole, and the like), and the like), or the like).
• an activated ester e.g., vinyl ester, propargyl ester, 2, 4-dinitrophenyl ester, pentafluorophenyl ester, methanesulfonylphenyl ester, dimethylimin
• the reaction is preferably carried out in the presence of condensing agent (including carbodiimide (e.g., N,N-diisopropylcarbodiimide, N, N'- dicyclohexylcarbodiimide, 1- [3- (dimethylamino) propyl] - 3-ethylcarbodiimide, and the like) , diphenylphosphinic azido, diphenylphosphonic chloride, or the like) .
• condensing agent including carbodiimide (e.g., N,N-diisopropylcarbodiimide, N, N'- dicyclohexylcarbodiimide, 1- [3- (dimethylamino) propyl] - 3-ethylcarbodiimide, and the like) , diphenylphosphinic azido, diphenylphosphonic chloride, or the like) .
• this reaction in the present reaction is usually carried out in the presence of an additive such as N- hydroxybenzotriazole (HOBt), l-hydroxy-7- azabenzotriazole (HOAt), bis(2-oxo-3- oxazolydinyl ) phosphinic chloride, and the like.
• an additive such as N- hydroxybenzotriazole (HOBt), l-hydroxy-7- azabenzotriazole (HOAt), bis(2-oxo-3- oxazolydinyl ) phosphinic chloride, and the like.
• the reaction may be also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri ( lower) alkylamine, pyridine, N- (lower ) alkylmorphorine, N, N- di (lower) alkylbenzylamine, or the like.
• an organic or inorganic base such as an alkali metal bicarbonate, tri ( lower) alkylamine, pyridine, N- (lower ) alkylmorphorine, N, N- di (lower) alkylbenzylamine, or the like.
• the reaction is usually carried out in a conventional solvent such as water, acetone, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like), tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N, N-dimethylformamide, or any other organic solvents which do not adversely affect the reaction or the mixture thereof.
• a conventional solvent such as water, acetone, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like), tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N, N-dimethylformamide, or any other organic solvents which do not adversely affect the reaction or the mixture thereof.
• reaction temperature is not limited and the reaction is usually carried out under cooling to heating .
• This reaction is elimination reaction of amino protective group of the compound (Ilia) or a salt thereof. And this reaction is also the reaction of methyl ester moiety of the compound (Ilia) or the salt thereof to carboxylic acid.
• the object compound (Ib) or a salt thereof can be prepared from the compound (lib) by a series of reaction that contains introduction of protected amino acid, deprotection and cyclization as illustrated aforementioned. And each reaction can be carried out in the same manner as in the aforementioned Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1.
• Process 3
• the object compound (Ic) or a salt thereof can be prepared from the compound (lie) by a series of reaction that contains introductions of protected amino acid and deprotection reactions each twice, and cyclization as illustrated aforementioned. And each reaction can be carried out in the same manner as in the aforementioned Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1.
• Process 4 The object compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) to catalytic hydrogenation .
• Suitable catalysts to be used in the' catalytic hydrogenation are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, palladium hydroxide on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), and the like.
• platinum catalysts e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
• palladium catalysts e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, palladium hydroxide on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.
• the hydrogenation is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N, N-dimethylformamide, N, N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
• a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N, N-dimethylformamide, N, N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
• reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
• the compound (IX) or a salt thereof can be prepared from the compound (VII) or a salt thereof by the following processes .
• a) Rearrangement This reaction is the rearrangement of the compound (VII) .
• the reaction is usually carried out in the presence of acid (such as trifluoroacetic acid, sulfuric acid, methanesulfonic acid, or the like) .
• acid such as trifluoroacetic acid, sulfuric acid, methanesulfonic acid, or the like
• the reaction is usually carried out in a conventional solvent such as water, acetone, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like), tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N, N-dimethylformamide, or any other organic solvents which do not adversely affect the reaction or the mixture thereof.
• the reaction temperature is not limited and the reaction is usually carried out under cooling to heating .
• This reaction of the present invention because of and owing to the substrate, can be carried out under the mild condition such as mild acid (p-toluenesulfonic acid) and mild temperature (ambient temperature to warming) to give a compound selectively subjected the rearrangement reaction.
• mild acid p-toluenesulfonic acid
• mild temperature ambient temperature to warming
• the reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like) , tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N, N- dimethylformamide, or any other organic solvents which do not adversely affect the reaction or the mixture thereof.
• a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like) , tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N, N- dimethylformamide, or any other organic solvents which do not adversely affect the reaction or the mixture thereof.
• the reaction temperature is not limited and the reaction is usually carried out under cooling to heating.
• the compound (IX) or a salt thereof can be prepared from the compound (VIII) or a salt thereof by hydrolysis.
• the hydrolysis is preferably carried out in the presence of a base (including an inorganic base and organic base such as alkali metal (e.g., sodium, potassium, etc.), alkaline earth metal (e.g., magnesium, calcium, etc.), the hydroxide or carbonate or bicarbonate of alkali metal or alkaline earth metal, trialkylamine (e.g., trimethylamine, etc.), hydrazine, picoline, 1, 5-diazabicyclo [4.3.0] non-5-ene, 1,8- diazabicyclo (5.4.0] undec-7-ene, or the like) or an acid (including an organic acid (e.g., formic acid, acetic acid, propanoic acid, trifluoroacetic acid, etc.), an inorganic acid (e.g., hydrobromic acid, sulfuric acid, hydrochloric acid, etc.
• the reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N- dimethylformamide, or any other organic solvent which does not adversely affect the reaction or the mixture thereof .
• a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N- dimethylformamide, or any other organic solvent which does not adversely affect the reaction or the mixture thereof .
• a liquid base or acid can be also used as the solvent.
• the reaction temperature is not limited and the reaction is usually carried out under cooling to heating.
• the compound (II) or a salt thereof can be prepared from the compound (IX) or a salt thereof by the following processes.
• a) reaction with (X) This reaction is the amidation of the compound (IX) with the compound (X) , so this reaction can be carried out in the same manner as in the aforementioned Process 1-a) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1-a).
• This reaction can be carried out by the method disclosed in Preparation 90 mentioned later or the similar manners thereto.
• b) deprotection This reaction can be carried out in the same manner as in the aforementioned Process 1-b) , and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1-b) .
• This reaction can be carried out by the method disclosed in Preparation 152 mentioned later or the similar manners thereto.
• the reaction is usually carried out in a conventional solvent such as water, acetonitrile, acetone, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like) , tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, ethyl acetate, N, N- dimethylformamide, or any other organic solvent which does not adversely affect the reaction or the mixture thereof .
• a conventional solvent such as water, acetonitrile, acetone, alcohol (e.g., methanol, ethanol, isopropyl alcohol, or the like) , tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, ethyl acetate, N, N- dimethylformamide, or any other organic solvent which does not adversely affect the reaction or the mixture thereof .
• the reaction temperature is not limited and the reaction is usually carried out under cooling to heating. And the reaction is carried out repeatedly until the object compound can be obtained.
• This reaction can be carried out by the method disclosed in Preparations 138, a series of 2 and 3, etc. mentioned later or the similar manners thereto (e.g., M, K. Eberle et al., J. Orq . Chem. 59, 7249-7258 (1994) described about this type Edman degradation method) .
• the compound (VII) or a salt thereof (FR901459 compound) can be produced by fermentation of fungus (Stachybotrys chartarum No.19392 : deposit number FERM BP- 3364) according to the method described in Japanese Laid-open Patent Application Hei 5-271267, for example.
• the object compound can be prepared by the processes described in Examples in the present application or similar processes.
• the compounds obtained by the above-mentioned processes 1 to 4 and A and B can be isolated and purified by a conventional method, such as pulverization, recrystallization, column chromatography, high performance liquid chromatography, reprecipitation and demineralized resin column chromatography.
• Suitable salts of the object compound (I) are conventional pharmaceutically acceptable and non-toxic salts, and may be a salt with a base or an acid addition salt, for example, a salt with an inorganic base (such as an alkali metal salt, e.g. sodium salt, potassium salt, etc., an alkaline earth metal salt, e.g. calcium salt, magnesium salt, etc., an ammonium salt), a salt with an organic base (such as an organic amine salt, e.g.
• an inorganic base such as an alkali metal salt, e.g. sodium salt, potassium salt, etc., an alkaline earth metal salt, e.g. calcium salt, magnesium salt, etc., an ammonium salt
• an organic base such as an organic amine salt, e.g.
• triethylamine salt diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N ' N ' -dibenzylethylenediamine salt, etc.
• an inorganic acid addition salt such as hydrochloride, hydrobromide, sulfate, phosphate, etc.
• an organic carboxylic acid or sulfonic acid addition salt such as formate, acetate, trifluoroacetate, maleate, tartrate, gluconate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.
• a salt with a basic or acidic amino acid such as arginine, aspartic acid, glutamic acid, etc.
• lower is intended a group having 1 to 6, preferably 1 to 4, unless otherwise indicated.
• Suitable examples of “lower alkyl” and “lower alkyl” moiety may include a straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl, and the like.
• Suitable examples of "lower alkoxy” and “lower alkoxy” moiety may include a straight or branched one having 1 to 6 carbon atom(s)-, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pentyloxy, neopentyloxy, hexyloxy, isohexyloxy, and the like.
• Suitable examples of "cyclo ( lower) alkyl” may include cyclic alkyl having 3 to 6 carbon atom, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and the like.
• aryl and “aryl” moiety may include phenyl which may be substituted with lower alkyl (e.g., phenyl, mesityl, tolyl, etc.), naphthyl, anthryl, tetrahydronaphthyl, indenyl, tetrahydroindenyl, and the like.
• Suitable examples of "optionally substituted amino” may include amino which is optionally substituted by one or two suitable substitutent (s) such as lower alkyl, amino protective group (e.g., benzyloxycarbonyl, t- butoxycarbonyl (Boc) and the like) and the like.
• Suitable examples of "optionally substituted carbamoyloxy” may include carbamoyloxy which is optionally substituted by one or two suitable substitutent (s) such as lower alkyl, amino protective group (e.g., benzyloxycarbonyl, t-butoxycarbonyl (Boc) and the like) and the like.
• suitable substitutent e.g., lower alkyl, amino protective group (e.g., benzyloxycarbonyl, t-butoxycarbonyl (Boc) and the like) and the like.
• heterocyclic group may include: unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1, 2, 4-triazolyl, IH-I, 2, 3- triazolyl, 2H-1, 2, 3-triazolyl, etc.), tetrazolyl (e.g.
• N-containing heterocyclic group can be referred to the ones as mentioned above, wherein the heterocyclic group is containing at least one nitrogen atom such as pyrrolidinyl, piperidyl, morpholinyl, thiazolyl, oxazolyl, and the like.
• Suitable “optionally substituted heterocyclic group” may include the heterocyclic group as mentioned above, which is optionally substituted by a suitable substituent such as lower alkyl, lower alkoxy, aryl, amino, lower alkoxycarbonyl, and the like.
• halogen means fluorine, chlorine, bromine and iodine.
• the method for evaluating the activity of the compound (I) for inhibiting RNA replication in accordance with the present invention is based on the cellular assay method that uses Huh-7 cells in which subgenomic HCV RNA is introduced.
• the inhibitory activity of the test compounds against the replication of HCV replicon was evaluated by quantified the activity of luciferase, a reporter gene product encoded in the replicon syetem reported by Yokota et al., EMBO 4 : 602-608 (2003) .
• the enzyme assay was carried out according to the technical manual of the Steady-Glo® luciferase assay system (Promega).
• the replicon assay was carried out with the modified method reported by Lohmann et al., Science 285: 110 (1999). The details are described in the following.
• the luciferase activities in replicon cells treated at each concentrations of the compound were employed for the calculation of EC50 value of the each compound, which gave the compound concentration indicating 50% enzyme activity level to the control (no drug group, containing only DMSO) .
• the anti-HCV agent in the present invention containing the compound (I) or a salt thereof as an active ingredient, can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, in admixture with an organic or inorganic carrier or excipient suitable for oral; sublingual; buccal; nasal; respiratory; parenteral (intracutaneous, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, central-venous, hepatic- venous, peripheral-venous, lymphatic, cardiovascular, arterial, ocular including injection around eye or intravenous drip around eye) ; intravenous drip into eyeball, augen structure or augen layer; aural including auditory canal, papillary chamber, external and internal auditory canals, drum membrane, tympanum, internal-auditory including spiralis cochleae ganglion, labyrinth, etc.; intestinal; rectal; vaginal; ureteral; and vesical administration.
• parenteral administration is preferable since administration is carried out in maternal blood vessels, or in vacancies, such as maternal organs including uterus, uterine cervix and vagina; fetal embryo, fetus, neonate, and combination tissue; and amnion, umbilical cord, umbilical artery and vein; placenta, and the like. Use of these passages is changed depending on the condition of each patient.
• the compound (I) or a salt thereof can be administered independently as a therapeutic agent or may be desired to be used as part of prescribed drugs.
• the "anti-HCV agent" in accordance with the present invention can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, in admixture with at least one or some suitable organic or inorganic carriers or excipients, or other pharmacological therapeutic agents.
• the active ingredient can be compounded with, for example, usual pharmacologically acceptable and non-toxic carriers in a solid form, such as granules, tablets, pellets, troches, capsules or suppositories; creams; ointments: aerosols; powders for insufflation; in a liquid form, such as solutions, emulsions or suspensions for injection; oral ingestion; eye drops; and any other forms suitable for use. And, if necessary, there may be included in the above preparations auxiliary substances, such as stabilizing, thickening, wetting, hardening and coloring agents; perfumes or buffers; or any other additives used commonly.
• auxiliary substances such as stabilizing, thickening, wetting, hardening and coloring agents; perfumes or buffers; or any other additives used commonly.
• the compound (I) or a pharmaceutically acceptable salt thereof is/are included in the pharmaceutical composition in an amount sufficient to produce the desired anti-hepatitis C effect upon the process or condition of diseases.
• the composition for applying the composition to humans, it is preferable to apply it by intravenous, intramuscular, pulmonary, oral administration, eye drop administration or insufflation.
• a daily dose of 0.001-400 mg of the compound (I) per kg weight of human being in the case of intramuscular administration a daily dose of 0.1-20 mg of the compound (I) per kg weight of human being, in case of oral administration, a daily dose of 0.5-50 mg of the compound (I) per kg weight of human being is generally given for treating or preventing hepatitis C.
• these doses may be required to exceed the limit thereof to obtain therapeutic results.
• the amount of the lipopeptide compound (I) or its pharmaceutically acceptable salt contained in the composition for a single unit dosage of the present invention is 0.1 to 400 mg, more preferably 1 to 200 mg, still more preferably 5 to 100 mg, specifically 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 and 100 mg .
• the present invention may include an article of manufacture, comprising packaging material and the compound (I) identified in the above contained within said packaging material, wherein said the compound (I) is therapeutically effective for preventing or treating hepatitis C, and wherein said packaging material comprises a label or a written material which indicates that said compound (I) can or should be used for preventing or treating hepatitis C.
• the present invention may include a commercial package comprising the pharmaceutical composition containing the compound (I) identified in the above and a written matter associated therewith, wherein the written matter states that the compound (I) can or should be used for preventing or treating hepatitis C.
• the compound (I) or a salt thereof may include one or more stereoisomer (s) , such as optical isomer (s) and geometrical isomer (s), due to asymmetric carbon atom(s) and double bond(s), and that all such isomers and the mixture thereof are included within the scope of the present invention.
• stereoisomer such as optical isomer (s) and geometrical isomer (s)
• the compound (I) or a salt thereof may include solvated compound (e.g. hydrate, ethanolate, etc.).
• the compound (I) or a salt thereof may include both the crystal form and non-crystal form.
• the compound (I) or a salt thereof may include the prodrug form.
• the object compound of Prep.90 (6.00 g) was dissolved in 20% TFA in CH 2 Cl 2 (80 ml) under ice-bath cooling and the mixture was stirred at the same temperature for 4 hrs. To the solution was added saturated NaHCO 3 aqueous solution to be pH 8 and the mixture was extracted with CHCl 3 (200 ml) .
• the compound of Prep.160 was obtained in a similar manner to that of Prep.159.
• the object compound of Ex.25 below (1.00 g) was dissolved in 10% TFA in CH 2 Cl 2 (10 ml) under ice-bath cooling. After being stirred at the same temperature for 2 hrs, to the reaction solution was added IM NaHCO 3 aqueous solution to be pH 8. The reaction mixture was extracted with CHCl 3 (50 ml) and the organic layer was washed with saturated NaHCO 3 aqueous solution and brine, dried over MgSO 4 , and concentrated in vacuo.
• the crude powder was purified by Silica-gel column chromatography (eluent: 4% MeOH in CHCl 3 ) to give (3S, 6S,9S,12R, 15S, 18S,21S,24S, 30S,33S) -24-(l-tert- butoxyethyl)-30-[ ( IR) -1-hydroxyethyl ] -33- [ ( IR, 2R, 4E) -1- hydroxy-2-methyl-4-hexen-l-yl] -6, 9, 18, 21-tetraisobutyl-3- isopropyl-1, 4, 10, 12, 15, 19, 25, 28-octamethyl- 1,4,7,10,13,16,19,22,25,28, 31-undecaazacyclotritriacontane- 2, 5, 8, 11, 14, 17,20,23,26,29, 32-undecone (448 mg) as an amorphous powder.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Virology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (14)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=37847219

Family Applications (1)

Country Status (17)

Cited By (13)

Families Citing this family (1)

Citations (3)

Family Cites Families (6)

• 2006
  • 2006-10-26 KR KR1020087012431A patent/KR101273681B1/ko not_active Expired - Fee Related
  • 2006-10-26 US US12/083,551 patent/US7872097B2/en active Active
  • 2006-10-26 PT PT68228444T patent/PT1957518E/pt unknown
  • 2006-10-26 BR BRPI0617781-6A patent/BRPI0617781A2/pt not_active Application Discontinuation
  • 2006-10-26 TW TW095139941A patent/TWI391403B/zh not_active IP Right Cessation
  • 2006-10-26 JP JP2008521463A patent/JP5218051B2/ja not_active Expired - Fee Related
  • 2006-10-26 AU AU2006306974A patent/AU2006306974B2/en not_active Ceased
  • 2006-10-26 ES ES06822844.4T patent/ES2557477T3/es active Active
  • 2006-10-26 PL PL06822844T patent/PL1957518T3/pl unknown
  • 2006-10-26 RU RU2008116674/04A patent/RU2423377C2/ru not_active IP Right Cessation
  • 2006-10-26 EP EP06822844.4A patent/EP1957518B1/en active Active
  • 2006-10-26 CA CA2623898A patent/CA2623898C/en not_active Expired - Fee Related
  • 2006-10-26 WO PCT/JP2006/321924 patent/WO2007049803A1/en not_active Ceased
  • 2006-10-26 CN CN2006800390294A patent/CN101305019B/zh not_active Expired - Fee Related
• 2008
  • 2008-03-19 IL IL190286A patent/IL190286A0/en unknown
  • 2008-04-22 ZA ZA2008/03525A patent/ZA200803525B/en unknown
  • 2008-05-23 NO NO20082354A patent/NO20082354L/no not_active Application Discontinuation
• 2010
  • 2010-07-21 US US12/840,488 patent/US8252895B2/en not_active Expired - Fee Related

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events